Posted in

News

Zolgensma-Evrysdi Combo Likely Beneficial for SMA Type 1

August 6, 2021

PepGen raises $113M to challenge Sarepta in DMD

August 5, 2021

Sarepta Acquires Investigational Gene Therapy for LGMD2A

August 4, 2021

Novartis announces lift of FDA clinical hold and plans to initiate a new, pivotal Phase 3 study

August 3, 2021

Novartis Stopping Work on Branaplam as Oral SMA Therapy

July 26, 2021

Long-term Viltepso Prevents Motor Function Decline in DMD

July 1, 2021

Data for Roche’s Evrysdi® (risdiplam) published in New England Journal of Medicine

June 29, 2021

New Genentech Data for Evrysdi (risdiplam) Show Improved Motor Function

June 11, 2021

New Tool Shows Profound Metabolic Changes in DMD Patients’ Muscles

April 27, 2021

New Zolgensma data demonstrate age-appropriate development

March 15, 2021